Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study

Department of Neurology, University of San Francisco, 350 Parnassus Ave, Suite 609, San Francisco, CA 94117, USA.
Journal of Neuro-Oncology (Impact Factor: 2.79). 01/2011; 101(2):267-77. DOI: 10.1007/s11060-010-0255-0
Source: PubMed

ABSTRACT The PRECISE study used convection enhanced delivery (CED) to infuse IL13-PE38QQR in patients with recurrent glioblastoma multiforme (GBM) and compared survival to Gliadel Wafers (GW). The objectives of this retrospective evaluation were to assess: (1) catheter positioning in relation to imaging features and (2) to examine the potential impact of catheter positioning, overall catheter placement and imaging features on long term clinical outcome in the PRECISE study. Catheter positioning and overall catheter placement were scored and used as a surrogate of adequate placement. Imaging studies obtained on day 43 and day 71 after resection were each retrospectively reviewed. Catheter positioning scores, catheter overall placement scores, local tumor control and imaging change scores were reviewed and correlated using Generalized Linear Mixed Models. Cox PH regression analysis was used to examine whether these imaging based variables predicted overall survival (OS) and progression free survival (PFS) after adjusting for age and KPS. Of 180 patients in the CED group, 20 patients did not undergo gross total resection. Of the remaining 160 patients only 53% of patients had fully conforming catheters in respect to overall placement and 51% had adequate catheter positioning scores. Better catheter positioning scores were not correlated with local tumor control (P = 0.61) or imaging change score (P = 0.86). OS and PFS were not correlated with catheter positioning score (OS: P = 0.53; PFS: P = 0.72 respectively), overall placement score (OS: P = 0.55; PFS: P = 0.35) or imaging changes on day 43 MRI (P = 0.88). Catheter positioning scores and overall catheter placement scores were not associated with clinical outcome in this large prospective trial.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In spite of aggressive multi-modality treatments, patients diagnosed with anaplastic astrocytoma and glioblastoma continue to display poor median survival. The success of our current conventional and targeted chemotherapies are largely hindered by systemic- and neurotoxicity, as well as poor central nervous system (CNS) penetration. Interstitial drug administration via convection-enhanced delivery (CED) is an alternative that potentially overcomes systemic toxicities and CNS delivery issues by directly bypassing the blood-brain barrier (BBB). This novel approach not only allows for directed administration, but also allows for newer, tumor-selective agents, which would normally be excluded from the CNS due to molecular size alone. To date, randomized trials of CED therapy have yet to definitely show survival advantage as compared with today's standard of care, however, early studies appear to have been limited by "first generation" delivery techniques. Taking into consideration lessons learned from early trials along with decades of research, newer CED technologies and therapeutic agents are emerging, which are reviewed herein.
    Surgical Neurology International 02/2015; 6(Suppl 1):S59-67. DOI:10.4103/2152-7806.151337 · 1.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: High-grade glioma (HGG) are optimally treated with maximum safe surgery, followed by radiotherapy (RT) and/or systemic chemotherapy (CT). Recently, the treatment of newly diagnosed anaplastic glioma (AG) has changed, particularly in patients with 1p19q codeleted tumors. Results of trials currenlty ongoing are likely to determine the best standard of care for patients with noncodeleted AG tumors. Trials in AG illustrate the importance of molecular characterization, which are germane to both prognosis and treatment. In contrast, efforts to improve the current standard of care of newly diagnosed glioblastoma (GB) with, for example, the addition of bevacizumab (BEV), have been largely disappointing and furthermore molecular characterization has not changed therapy except in elderly patients. Novel approaches, such as vaccine-based immunotherapy, for newly diagnosed GB are currently being pursued in multiple clinical trials. Recurrent disease, an event inevitable in nearly all patients with HGG, continues to be a challenge. Both recurrent GB and AG are managed in similar manner and when feasible re-resection is often suggested notwithstanding limited data to suggest benefit from repeat surgery. Occassional patients may be candidates for re-irradiation but again there is a paucity of data to commend this therapy and only a minority of selected patients are eligible for this approach. Consequently systemic therapy continues to be the most often utilized treatment in recurrent HGG. Choice of therapy, however, varies and revolves around re-challenge with temozolomide (TMZ), use of a nitrosourea (most often lomustine; CCNU) or BEV, the most frequently used angiogenic inhibitor. Nevertheless, no clear standard recommendation regarding the prefered agent or combination of agents is avaliable. Prognosis after progression of a HGG remains poor, with an unmet need to improve therapy.
    Surgical Neurology International 02/2015; 6(Suppl 1):S9-S44. DOI:10.4103/2152-7806.151331 · 1.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An axisymmetric biphasic finite element model is proposed to simulate the backflow that develops around the external boundary of the catheter during flow-controlled infusions. The model includes both material and geometric nonlinearities and special treatments for the nonlinear boundary conditions used to represent the forward flow from the catheter tip and the axial backflow that occurs in the annular gap that develops as the porous medium detaches from the catheter. Specifically, a layer of elements with high hydraulic conductivity and low Young's modulus was used to represent the nonlinear boundary condition for the forward flow, and another layer of elements with axial hydraulic conductivity consistent with Poiseuille flow was used to represent the backflow. Validation of the model was performed by modifying the elastic properties of the latter layer to fit published experimental values for the backflow length and maximum fluid pressure obtained during infusions into agarose gels undertaken with a 0.98-mm-radius catheter. Next, the finite element model predictions showed good agreement with independent experimental data obtained for 0.5-mm-radius and 0.33-mm-radius catheters. Compared to analytical models developed by others, this finite element model predicts a smaller backflow length, a larger fluid pressure, and a substantially larger percentage of forward flow. This latter difference can be explained by the important axial flow in the tissue that is not considered in the analytical models. These results may provide valuable guidelines to optimize protocols during future clinical studies. The model can be extended to describe infusions in brain tissue and in patient-specific geometries. [DOI: 10.1115/1.4007311]
    01/2012; 8(1):011017. DOI:10.1115/1.4007311

Full-text (3 Sources)

Available from
May 28, 2014